Form 144 | Steris PLC(STE.US) Officer Proposes to Sell 469.84K in Common Stocks
SEC FILLINGS DISCLOSED/ May 13, $Steris PLC(STE.US)$ Officer Majors Cary L intends to sell 2,024 shares of its common stock on May 13, with a total market value of approximately $469.84K. Source: A
Form 144 | Steris PLC(STE.US) Director Proposes to Sell 1.06 Million in Common Stocks
SEC FILLINGS DISCLOSED/ May 13, $Steris PLC(STE.US)$ Director KOSECOFF JACQUELINE B intends to sell 4,584 shares of its common stock on May 13, with a total market value of approximately $1.06 million
These 10 Large Cap Stocks Shined Brightest Last Week (May 5-May 11, 2024): Are They In Your Portfolio?
These large-cap stocks were the best performers in the last week. Are they in your portfolio?Teva Pharmaceutical Industries (NYSE:TEVA) shares surged 16.24% after the company reported mixed Q1 financi
Steris PLC Fiscal 2024 Earnings: Surpasses Revenue Forecasts and Adjusted EPS Expectations
STERIS Plc (NYSE:STE) Q4 2024 Earnings Call Transcript
Piper Sandler Reiterates Neutral on Steris, Raises Price Target to $225
Piper Sandler analyst Jason Bednar reiterates Steris (NYSE:STE) with a Neutral and raises the price target from $220 to $225.
US bullish stocks this week | Electric power stocks are popular! Vistra and Constellation both recorded double-digit gains
Good performance boosts stock prices! AppLovin, International Fragrances and Fragrances, and Emerson Electric increased by 12.81%, 12.03%, and 8.49% respectively during the week.
KeyBanc Adjusts Price Target on STERIS to $255 From $253
STERIS (STE) has an average rating of outperform and price targets ranging from $215 to $265, according to analysts polled by Capital IQ.
Needham Reiterates Hold on Steris
Needham analyst Mike Matson reiterates Steris with a Hold.
Q4 2024 STERIS Plc Earnings Call
J.P. Morgan Securities: Reiterated the Steris (STE.US) rating and adjusted from superior to superior market rating, with a target price of $265.00.
J.P. Morgan Securities: Reiterated the Steris (STE.US) rating and adjusted from superior to superior market rating, with a target price of $265.00.
JMP Securities Reiterates Market Outperform on Steris, Maintains $265 Price Target
JMP Securities analyst David Turkaly reiterates Steris with a Market Outperform and maintains $265 price target.
Steris Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/09/2024 18.71% JMP Securities → $265 Reiterates Market Outperform → Market Outperform 04/12/2024 — Need
Earnings Call Summary | Steris PLC(STE.US) Q4 2024 Earnings Conference
The following is a summary of the STERIS Plc (STE) Q4 2024 Earnings Call Transcript:Financial Performance:STERIS Plc reported total Q4 revenue growth of 10%, with adjusted earnings per diluted share a
STERIS Plc (STE) Q4 2024 Earnings Call Transcript
STERIS plc (STE) Q4 2024 Earnings Call Transcript
STERIS (STE) Q4 Earnings Match Estimates, Margins Contract
STERIS plc STE reported fourth-quarter fiscal 2024 adjusted earnings per share (EPS) of $2.41, up 4.8% from the year-ago quarter's figure.
STERIS Shares Are Trading Higher After the Company Reported Better-than-expected Q4 Financial Results. The Company Announced Planned Restructuring of Its Healthcare Surgical Business in Europe.
STERIS Shares Are Trading Higher After the Company Reported Better-than-expected Q4 Financial Results. The Company Announced Planned Restructuring of Its Healthcare Surgical Business in Europe.
STERIS on Pace for Largest Percent Increase Since May 2023 -- Data Talk
STERIS plc (STE) is currently at $220.66, up $10.58 or 5.03% --Would be highest close since April 1, 2024, when it closed at $221.03 --On pace for largest percent increase since May 11, 2023, when i
Steris Fiscal Q4 Non-GAAP EPS, Revenue Rise; Fiscal 2025 Outlook Set -- Share Rise After Hours
Steris (STE) reported fiscal Q4 adjusted net income late Wednesday of $2.58 per diluted share, up from $2.30 a year earlier. Analysts polled by Capital IQ expected $2.35. Revenue for the quarter ended
STERIS Expects FY25 As Reported Revenue From Continuing Operations To Increase 6.5%-7.5%; Adjusted EPS From Continuing Operations Of $9.05 - $9.25 (Est $9.33)
Capital expenditures are anticipated to be approximately $360 million and free cash flow is expected to be approximately $700 million.
No Data